MOUSE ANTI HUMAN C3b

Published customer image:
Mouse anti Human C3b antibody, clone H11 (0200-0614) used for the evaluation of C3b expression on CD59 positive and negative populations of human erythrocytes by flow cytometry.
Image caption:
In vivo C3 binding on red cells of PNH patients on eculizumab. a Kinetics of C3 binding on red cells from a representative PNH patient during eculizumab treatment. Before treatment (0 week), no red cell binds C3, whereas starting from 1 week of treatment three populations of red cells are displayed: one population of normal red cells (CD59 + C3−) and two distinct populations of PNH (CD59-negative) red cells, one with (C3+) and one without (C3−) fragments bound on their surface. b Characterization of C3 fragment bound to erythrocytes from PNH patient on eculizumab. The left panel shows the normal (CD59-positive) and PNH (CD59-negative) populations (gated by the elliptic mark). The PNH (CD59-negative) population (see gate in the left panel) has been analyzed with anti-C3d and either anti-C3b (middle panel) or anti-iC3b (left panel). SSC: side scatter

From: Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R.
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
.

Published customer image:
Mouse anti Human C3b antibody, clone H11 (0200-0614) used for the evaluation of C3b expression on CD59 positive and negative populations of human erythrocytes by flow cytometry.
Image caption:
In vivo C3 binding on red cells of PNH patients on eculizumab. a Kinetics of C3 binding on red cells from a representative PNH patient during eculizumab treatment. Before treatment (0 week), no red cell binds C3, whereas starting from 1 week of treatment three populations of red cells are displayed: one population of normal red cells (CD59 + C3−) and two distinct populations of PNH (CD59-negative) red cells, one with (C3+) and one without (C3−) fragments bound on their surface. b Characterization of C3 fragment bound to erythrocytes from PNH patient on eculizumab. The left panel shows the normal (CD59-positive) and PNH (CD59-negative) populations (gated by the elliptic mark). The PNH (CD59-negative) population (see gate in the left panel) has been analyzed with anti-C3d and either anti-C3b (middle panel) or anti-iC3b (left panel). SSC: side scatter

From: Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R.
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
J Hematol Oncol. 2017 Jun 19;10(1):126.